An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR, Inc. (Nasdaq: LNSR) will report its first quarter 2024 financial results on Thursday, May 9, 2024. The global medical technology company specializing in femtosecond laser solutions for cataract treatment will host a conference call and webcast to discuss the results and recent corporate highlights.
Positive
None.
Negative
None.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (800) 267 6316 (Domestic) or (203) 518 9783 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
When will LENSAR report its first quarter 2024 financial results?
LENSAR will report its first quarter 2024 financial results on Thursday, May 9, 2024.
What is LENSAR's stock symbol?
LENSAR's stock symbol is LNSR.
Where can I access the live webcast of LENSAR's conference call?
You can access the live webcast of LENSAR's conference call in the Investors section of LENSAR's website at www.lensar.com.
How can I participate in LENSAR's conference call by telephone?
To participate in LENSAR's conference call by telephone, dial (800) 267 6316 (Domestic) or (203) 518 9783 (International) with the conference ID as LENSAR.
lensar® is the leader in next-generation femtosecond laser technology for refractive cataract surgery. the lensar laser system offers cataract surgeons precision and accuracy, while optimizing overall visual outcomes. the proprietary augmented reality™, lensar’s reconstructed 3-d imaging, measurement, and guidance system, provides high-resolution ocular images in a single scan. this technology facilitates precise surgical incisions and treatment for ultimate accuracy and reliable outcomes, all in a single procedure room. the lensar laser system is the only femtosecond cataract laser built specifically for refractive cataract surgery. because it was designed from the ground up, every aspect of the laser has been purposefully designed to meet the needs of cataract surgeons. lensar, inc. is committed to revolutionizing refractive eye surgery. our success depends on talented and motivated individuals who share our passion for making a difference in patients’ lives. we are a young and vibra
